Journal of Clinical Oncology, Vol 20, Issue 3
(February), 2002: 719-726
© 2002 American Society for Clinical Oncology
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
By Charles L. Vogel,
Melody A. Cobleigh,
Debu Tripathy,
John C. Gutheil,
Lyndsay N. Harris,
Louis Fehrenbacher,
Dennis J. Slamon,
Maureen Murphy,
William F. Novotny,
Michael Burchmore,
Steven Shak,
Stanford J. Stewart,
Michael Press
From University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL; Rush-Presbyterian-St Lukes Medical Center, Chicago, IL; University of California, San Francisco/Mount Zion Cancer Center, San Francisco; Sidney Kimmel Cancer Center, San Diego; Kaiser Permanente, Vallejo; University of California Los Angeles School of Medicine and University of Southern California School of Medicine, Los Angeles; Genentech, Inc, South San Francisco, CA; and Duke University Medical Center, Durham, NC.
Address reprint requests to Charles L. Vogel, MD, 600 South Pine Island Rd, Suite 104, Plantation, FL 33324.
PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer.
PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly.
RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events.
CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Joensuu, P. Bono, V. Kataja, T. Alanko, R. Kokko, R. Asola, T. Utriainen, T. Turpeenniemi-Hujanen, S. Jyrkkio, K. Moykkynen, et al.
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
J. Clin. Oncol.,
December 1, 2009;
27(34):
5685 - 5692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. L. Spector and K. L. Blackwell
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
J. Clin. Oncol.,
December 1, 2009;
27(34):
5838 - 5847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Roepman, H. M. Horlings, O. Krijgsman, M. Kok, J. M. Bueno-de-Mesquita, R. Bender, S. C. Linn, A. M. Glas, and M. J. van de Vijver
Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
Clin. Cancer Res.,
November 15, 2009;
15(22):
7003 - 7011.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Ma, Q. li, H. An, M. S. Pankonin, J. Wang, and J. A. Loeb
Targeting Human Epidermal Growth Factor Receptor Signaling with the Neuregulin's Heparin-binding Domain
J. Biol. Chem.,
November 13, 2009;
284(46):
32108 - 32115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. T.P. Kaumaya, K. C. Foy, J. Garrett, S. V. Rawale, D. Vicari, J. M. Thurmond, T. Lamb, A. Mani, Y. Kane, C. R. Balint, et al.
Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
J. Clin. Oncol.,
November 1, 2009;
27(31):
5270 - 5277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al.
Third consensus on medical treatment of metastatic breast cancer
Ann. Onc.,
November 1, 2009;
20(11):
1771 - 1785.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Huang, L. Gao, S. Wang, C.-K. Lee, P. Ordentlich, and B. Liu
HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
Cancer Res.,
November 1, 2009;
69(21):
8403 - 8411.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Penault-Llorca, M. Bilous, M. Dowsett, W. Hanna, R. Y. Osamura, J. Ruschoff, and M. van de Vijver
Emerging Technologies for Assessing HER2 Amplification
Am J Clin Pathol,
October 1, 2009;
132(4):
539 - 548.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. G. VAN ROOIJ, L. D.A. DORRESTEIJN, M. M.J.A. VAN BOKHOVEN, and C. C.P. VERSTAPPEN
A Throbbing Pain in the Head: Trastuzumab-induced Migraine
Anticancer Res,
October 1, 2009;
29(10):
4223 - 4225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone
Target-based therapies in breast cancer: current status and future perspectives
Endocr. Relat. Cancer,
September 1, 2009;
16(3):
675 - 702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. T. Okita, Y. Yamada, D. Takahari, Y. Hirashima, J. Matsubara, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, H. Taniguchi, et al.
Vascular Endothelial Growth Factor Receptor Expression as a Prognostic Marker for Survival in Colorectal Cancer
Jpn. J. Clin. Oncol.,
September 1, 2009;
39(9):
595 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, E. Tarco, S. Trivedi, W. F. Symmans, J. Isola, and N. Sneige
Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results: A Study of Two Institutions Using the Conventional and New ASCO/CAP Scoring Criteria
Am J Clin Pathol,
August 1, 2009;
132(2):
228 - 236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Mitra, M. J. Brumlik, S. U. Okamgba, Y. Zhu, T. T. Duplessis, J. G. Parvani, S. M. Lesko, E. Brogi, and F. E. Jones
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
Mol. Cancer Ther.,
August 1, 2009;
8(8):
2152 - 2162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Ann. Onc.,
July 24, 2009;
(2009)
mdp304v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Shah, T. W. Miller, S. K. Wyatt, E. T. McKinley, M. G. Olivares, V. Sanchez, D. D. Nolting, J. R. Buck, P. Zhao, M. S. Ansari, et al.
Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
Clin. Cancer Res.,
July 15, 2009;
15(14):
4712 - 4721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-H. Liu, F.-P. Xu, J.-Y. Rao, H.-G. Zhuang, X.-L. Luo, L. Li, D.-L. Luo, F. Zhang, and J. Xu
Justification of the Change From 10% to 30% for the Immunohistochemical HER2 Scoring Criterion in Breast Cancer
Am J Clin Pathol,
July 1, 2009;
132(1):
74 - 79.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. T.H. Yeh and C. L. Bickford
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.
J. Am. Coll. Cardiol.,
June 16, 2009;
53(24):
2231 - 2247.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. U. Buzdar
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
Ann. Onc.,
June 1, 2009;
20(6):
993 - 999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Eguchi, H. Itadani, T. Shimomura, N. Kawanishi, H. Hirai, and H. Kotani
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines
Mol. Cancer Ther.,
June 1, 2009;
8(6):
1460 - 1472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dokmanovic, D. S. Hirsch, Y. Shen, and W. J. Wu
Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer
Mol. Cancer Ther.,
June 1, 2009;
8(6):
1557 - 1569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kedrin, J. Wyckoff, P. J. Boimel, S. J. Coniglio, N. E. Hynes, C. L. Arteaga, and J. E. Segall
ERBB1 and ERBB2 Have Distinct Functions in Tumor Cell Invasion and Intravasation
Clin. Cancer Res.,
June 1, 2009;
15(11):
3733 - 3739.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bernards
Finding Biomarkers of Cancer Drug Resistance through RNA Interference-Based Genetic Screens
Am. Assoc. Cancer Res. Educ. Book,
April 18, 2009;
2009(1):
253 - 257.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al.
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Clin. Cancer Res.,
April 15, 2009;
15(8):
2895 - 2904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. T. Salvana and R. A. Salata
Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules
Clin. Microbiol. Rev.,
April 1, 2009;
22(2):
274 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, Y. Fang, J. Zhao, E. Tarco, W. F. Symmans, J. Isola, and N. Sneige
Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations
Am J Clin Pathol,
April 1, 2009;
131(4):
490 - 497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Lennon, C. Barton, L. Banken, L. Gianni, M. Marty, J. Baselga, and B. Leyland-Jones
Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
J. Clin. Oncol.,
April 1, 2009;
27(10):
1685 - 1693.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. Leary, W. M. Hanna, M. J. van de Vijver, F. Penault-Llorca, J. Ruschoff, R. Y. Osamura, M. Bilous, and M. Dowsett
Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
J. Clin. Oncol.,
April 1, 2009;
27(10):
1694 - 1705.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gori, A. Sidoni, M. Colozza, I. Ferri, M. G. Mameli, D. Fenocchio, L. Stocchi, J. Foglietta, V. Ludovini, E. Minenza, et al.
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
Ann. Onc.,
April 1, 2009;
20(4):
648 - 654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist,
April 1, 2009;
14(4):
320 - 368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Menard, and E. Tagliabue
Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab
Clin. Cancer Res.,
March 15, 2009;
15(6):
2010 - 2021.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
J. Clin. Oncol.,
March 10, 2009;
27(8):
1323 - 1333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Anton, A. Ruiz, M. A. Segui, L. Calvo, M. Munoz, J. Lao, F. Sancho, and L. Fernandez
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
Ann. Onc.,
March 1, 2009;
20(3):
454 - 459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. H. Park, J. Ro, K. S. Lee, B. H. Nam, Y. Kwon, and K. H. Shin
Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
Ann. Onc.,
January 1, 2009;
20(1):
56 - 62.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Cortes, S. Di Cosimo, M. A. Climent, H. Cortes-Funes, A. Lluch, P. Gascon, J. I. Mayordomo, M. Gil, M. Benavides, L. Cirera, et al.
Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
Clin. Cancer Res.,
January 1, 2009;
15(1):
307 - 314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Oncologist,
January 1, 2009;
14(1):
1 - 11.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Press, R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, A. Santiago, R. Guzman, A. Gasparyan, Y. Ma, et al.
HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
Clin. Cancer Res.,
December 1, 2008;
14(23):
7861 - 7870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al.
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Cancer Res.,
November 15, 2008;
68(22):
9280 - 9290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Chen, Y. Wang, S. E Kane, and S. Chen
Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells
J. Mol. Endocrinol.,
November 1, 2008;
41(5):
367 - 377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al.
Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists
J. Mol. Diagn.,
November 1, 2008;
10(6):
527 - 536.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. L. Chen, W. Xia, and N. L. Spector
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Clin. Cancer Res.,
November 1, 2008;
14(21):
6730 - 6734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Vanden Bempt, P. Van Loo, M. Drijkoningen, P. Neven, A. Smeets, M.-R. Christiaens, R. Paridaens, and C. De Wolf-Peeters
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
J. Clin. Oncol.,
October 20, 2008;
26(30):
4869 - 4874.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Rosenberg
Polysomy 17 and HER-2 Amplification: True, True, and Unrelated
J. Clin. Oncol.,
October 20, 2008;
26(30):
4856 - 4858.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg
Validation of Analytic Methods for Biomarkers Used in Drug Development
Clin. Cancer Res.,
October 1, 2008;
14(19):
5967 - 5976.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Arteaga, A. O'Neill, S. L. Moulder, M. Pins, J. A. Sparano, G. W. Sledge, and N. E. Davidson
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
Clin. Cancer Res.,
October 1, 2008;
14(19):
6277 - 6283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies
Ann. Onc.,
September 1, 2008;
19(9):
1530 - 1539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Costantini, K. Bateman, K. McLarty, K. A. Vallis, and R. M. Reilly
Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate
J. Nucl. Med.,
September 1, 2008;
49(9):
1498 - 1505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Guarneri, S. Giovannelli, G. Ficarra, S. Bettelli, A. Maiorana, F. Piacentini, E. Barbieri, M. V. Dieci, R. D'Amico, G. Jovic, et al.
Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management
Oncologist,
August 1, 2008;
13(8):
838 - 844.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. Lee-Hoeflich, L. Crocker, E. Yao, T. Pham, X. Munroe, K. P. Hoeflich, M. X. Sliwkowski, and H. M. Stern
A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
Cancer Res.,
July 15, 2008;
68(14):
5878 - 5887.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. S.C. Chu, M. E. Cianfrocca, L. J. Goldstein, M. Gale, N. Murray, J. Loftiss, N. Arya, K. M. Koch, L. Pandite, R. A. Fleming, et al.
A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer
Clin. Cancer Res.,
July 15, 2008;
14(14):
4484 - 4490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Storniolo, M. D. Pegram, B. Overmoyer, P. Silverman, N. W. Peacock, S. F. Jones, J. Loftiss, N. Arya, K. M. Koch, E. Paul, et al.
Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer
J. Clin. Oncol.,
July 10, 2008;
26(20):
3317 - 3323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Rowe, T. Ozbay, L. M. Bender, and R. Nahta
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer
Mol. Cancer Ther.,
July 1, 2008;
7(7):
1900 - 1908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Del Mastro
The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients
Ann. Onc.,
July 1, 2008;
19(7):
1213 - 1215.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R A Walker, J M S Bartlett, M Dowsett, I O Ellis, A M Hanby, B Jasani, K Miller, and S E Pinder
HER2 testing in the UK: further update to recommendations
J. Clin. Pathol.,
July 1, 2008;
61(7):
818 - 824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Stemmler and V. Heinemann
Central Nervous System Metastases in HER-2-Overexpressing Metastatic Breast Cancer: A Treatment Challenge
Oncologist,
July 1, 2008;
13(7):
739 - 750.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al.
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer
J. Clin. Oncol.,
June 20, 2008;
26(18):
2999 - 3005.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Seruga and I. F. Tannock
Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500?
J. Clin. Oncol.,
June 20, 2008;
26(18):
2940 - 2942.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard
CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4
J. Immunol.,
June 15, 2008;
180(12):
8135 - 8145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella
Neuregulins and Cancer
Clin. Cancer Res.,
June 1, 2008;
14(11):
3237 - 3241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R A Walker
Immunohistochemical markers as predictive tools for breast cancer
J. Clin. Pathol.,
June 1, 2008;
61(6):
689 - 696.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Song, K. Shahverdi, D. L. Huso, C. Esaias, J. Fox, A. Liedy, Z. Zhang, R. T. Reilly, C. Apostolidis, A. Morgenstern, et al.
213Bi ({alpha}-Emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model
Cancer Res.,
May 15, 2008;
68(10):
3873 - 3880.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. B. Michaud
Treatment-experienced breast cancer
Am. J. Health Syst. Pharm.,
May 15, 2008;
65(10_Supplement_3):
S4 - S9.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Willis, N. L. Tran, J. M. Chatigny, N. Charlton, H. Vu, S. A.N. Brown, M. A. Black, W. S. McDonough, S. P. Fortin, J. R. Niska, et al.
The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity
Mol. Cancer Res.,
May 1, 2008;
6(5):
725 - 734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Portera, J. M. Walshe, D. R. Rosing, N. Denduluri, A. W. Berman, U. Vatas, M. Velarde, C. K. Chow, S. M. Steinberg, D. Nguyen, et al.
Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Clin. Cancer Res.,
May 1, 2008;
14(9):
2710 - 2716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Bullock and K. Blackwell
Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer
Oncologist,
May 1, 2008;
13(5):
515 - 525.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. U. Lin, L. A. Carey, M. C. Liu, J. Younger, S. E. Come, M. Ewend, G. J. Harris, E. Bullitt, A. D. Van den Abbeele, J. W. Henson, et al.
Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
J. Clin. Oncol.,
April 20, 2008;
26(12):
1993 - 1999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pant, M. B. Landon, M. Blumenfeld, W. Farrar, and C. L. Shapiro
Treatment of Breast Cancer With Trastuzumab During Pregnancy
J. Clin. Oncol.,
March 20, 2008;
26(9):
1567 - 1569.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. El-Maraghi and E. A. Eisenhauer
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
J. Clin. Oncol.,
March 10, 2008;
26(8):
1346 - 1354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
Ann. Onc.,
March 1, 2008;
19(3):
487 - 495.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C L Hyun, H E Lee, K S Kim, S-W Kim, J H Kim, G Choe, and S Y Park
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
J. Clin. Pathol.,
March 1, 2008;
61(3):
317 - 321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Haddad and D. Yee
Of Mice and (Wo)Men: Is This Any Way to Test a New Drug?
J. Clin. Oncol.,
February 20, 2008;
26(6):
830 - 832.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ocana and A. Pandiella
Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options
Clin. Cancer Res.,
February 15, 2008;
14(4):
961 - 970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, D. M. Ikeda, B. Narasimhan, T. A. Longacre, R. J. Bleicher, S. Pal, R. J. Jackman, and S. S. Jeffrey
Estrogen Receptor-Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression
Radiology,
February 1, 2008;
246(2):
367 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Aird, X. Ding, A. Baras, J. Wei, M. A. Morse, T. Clay, H. K. Lyerly, and G. R. Devi
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression
Mol. Cancer Ther.,
January 1, 2008;
7(1):
38 - 47.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Revillion, V. Lhotellier, L. Hornez, J. Bonneterre, and J.-P. Peyrat
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis
Ann. Onc.,
January 1, 2008;
19(1):
73 - 80.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R.J. H. Bird and S. M. Swain
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Clin. Cancer Res.,
January 1, 2008;
14(1):
14 - 24.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Hofmann, O Stoss, T Gaiser, H Kneitz, P Heinmoller, T Gutjahr, M Kaufmann, T Henkel, and J Ruschoff
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy
J. Clin. Pathol.,
January 1, 2008;
61(1):
89 - 94.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Selvarajan, L-H Sii, A Lee, G Yip, B-H Bay, M-H Tan, B-T Teh, and P-H Tan
Parafibromin expression in breast cancer: a novel marker for prognostication?
J. Clin. Pathol.,
January 1, 2008;
61(1):
64 - 67.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Munoz, S. Carrera, J. Ferreiro, A. Ruiz de Lobera, J. M. Mane, and G. Lopez-Vivanco
Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer
Ann. Onc.,
December 1, 2007;
18(12):
2045 - 2046.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sapino, F. Montemurro, C. Marchio, G. Viale, J. Kulka, M. Donadio, A. Bottini, G. Botti, A. P. dei Tos, A. Bersiga, et al.
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin(R) are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study
Ann. Onc.,
December 1, 2007;
18(12):
1963 - 1968.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Catania, M. Medici, E. Magni, E. Munzone, D. Cardinale, L. Adamoli, G. Sanna, I. Minchella, D. Radice, A. Goldhirsch, et al.
Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination
Ann. Onc.,
December 1, 2007;
18(12):
1969 - 1975.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
J. Clin. Oncol.,
November 20, 2007;
25(33):
5287 - 5312.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Garman, J. R. Nevins, and A. Potti
Genomic strategies for personalized cancer therapy
Hum. Mol. Genet.,
October 15, 2007;
16(R2):
R226 - R232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Jani, R. S. Finn, M. Campbell, K. G. Coleman, R. D. Connell, N. Currier, E. O. Emerson, E. Floyd, S. Harriman, J. C. Kath, et al.
Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor
Cancer Res.,
October 15, 2007;
67(20):
9887 - 9893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Pusztai, K. Anderson, and K. R. Hess
Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer
Clin. Cancer Res.,
October 15, 2007;
13(20):
6080 - 6086.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Orlandi, F. M. Venanzi, A. Concetti, H. Yamauchi, S. Tiwari, L. Norton, J. D. Wolchok, A. N. Houghton, and P. D. Gregor
Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine
Clin. Cancer Res.,
October 15, 2007;
13(20):
6195 - 6203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Lu, S. L. Wyszomierski, L.-M. Tseng, M.-H. Sun, K.-H. Lan, C. L. Neal, G. B. Mills, G. N. Hortobagyi, F. J. Esteva, and D. Yu
Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency
Clin. Cancer Res.,
October 1, 2007;
13(19):
5883 - 5888.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|